Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Histo-genomics: digital pathology at the forefront of precision medicine.

Barsoum I, Tawedrous E, Faragalla H, Yousef GM.

Diagnosis (Berl). 2018 Dec 20. pii: /j/dx.ahead-of-print/dx-2018-0064/dx-2018-0064.xml. doi: 10.1515/dx-2018-0064. [Epub ahead of print] Review.

PMID:
30827078
2.

Direct Quantitative Analysis of Multiple microRNAs (DQAMmiR) with Peptide Nucleic Acid Hybridization Probes.

Hu L, Anand M, Krylova SM, Yang BB, Liu SK, Yousef GM, Krylov SN.

Anal Chem. 2018 Dec 18;90(24):14610-14615. doi: 10.1021/acs.analchem.8b04793. Epub 2018 Dec 4.

PMID:
30451492
3.

Translational research: Empowering the role of pathologists and cytopathologists.

Khella HWZ, Yousef GM.

Cancer Cytopathol. 2018 Oct;126(10):831-838. doi: 10.1002/cncy.22046. Epub 2018 Oct 3.

PMID:
30281935
4.

Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.

Lichner Z, Saleeb R, Butz H, Ding Q, Nofech-Mozes R, Riad S, Farag M, Varkouhi AK, Dos Santos CC, Kapus A, Yousef GM.

FASEB J. 2019 Jan;33(1):1347-1359. doi: 10.1096/fj.201800596R. Epub 2018 Aug 27.

PMID:
30148679
5.

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.

Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion A, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst PC, Pili R.

Clin Cancer Res. 2018 Dec 1;24(23):5977-5989. doi: 10.1158/1078-0432.CCR-18-0269. Epub 2018 Jul 30.

PMID:
30061365
6.

Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.

Saleeb RM, Farag M, Lichner Z, Brimo F, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM.

Mol Oncol. 2018 Oct;12(10):1673-1688. doi: 10.1002/1878-0261.12346. Epub 2018 Aug 23.

7.

The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer.

Di Meo A, Wang C, Cheng Y, Diamandis EP, Yousef GM.

Biol Chem. 2018 Sep 25;399(9):973-982. doi: 10.1515/hsz-2018-0112. Review.

PMID:
29604203
8.

Manfred Schmitt (1947-2018).

Reuning U, Magdolen V, Courty Y, Clements JA, Yousef GM, Scorilas A, Talieri M, Diamandis EP.

Biol Chem. 2018 Sep 25;399(9):923-924. doi: 10.1515/hsz-2018-0184. No abstract available.

PMID:
29601294
9.

Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents.

Xu XR, Yousef GM, Ni H.

Blood. 2018 Apr 19;131(16):1777-1789. doi: 10.1182/blood-2017-05-743187. Epub 2018 Mar 8. Review.

PMID:
29519806
10.

miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2.

Wang C, Zhang W, Zhang L, Chen X, Liu F, Zhang J, Guan S, Sun Y, Chen P, Wang D, Un Nesa E, Cheng Y, Yousef GM.

Br J Cancer. 2018 Mar 20;118(6):e12. doi: 10.1038/bjc.2017.471. Epub 2018 Feb 20.

11.

Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis.

Butz H, Ding Q, Nofech-Mozes R, Lichner Z, Ni H, Yousef GM.

Oncotarget. 2017 Dec 8;9(4):4661-4674. doi: 10.18632/oncotarget.23163. eCollection 2018 Jan 12.

12.

A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization.

Di Meo A, Saleeb R, Wala SJ, Khella HW, Ding Q, Zhai H, Krishan K, Krizova A, Gabril M, Evans A, Brimo F, Pasic MD, Finelli A, Diamandis EP, Yousef GM.

Oncotarget. 2017 Dec 8;9(2):2092-2104. doi: 10.18632/oncotarget.23162. eCollection 2018 Jan 5.

13.

Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis.

Saleeb RM, Brimo F, Farag M, Rompré-Brodeur A, Rotondo F, Beharry V, Wala S, Plant P, Downes MR, Pace K, Evans A, Bjarnason G, Bartlett JMS, Yousef GM.

Am J Surg Pathol. 2017 Dec;41(12):1618-1629. doi: 10.1097/PAS.0000000000000962.

PMID:
28984673
14.

Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis.

Lichner Z, Mac-Way F, Yousef GM.

Eur Urol Focus. 2017 Aug 25. pii: S2405-4569(17)30195-5. doi: 10.1016/j.euf.2017.08.003. [Epub ahead of print] Review.

PMID:
28847686
15.

Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.

Saleeb RM, Plant P, Tawedrous E, Krizova A, Brimo F, Evans AJ, Wala SJ, Bartlett J, Ding Q, Boles D, Rotando F, Farag M, Yousef GM.

Eur Urol Focus. 2018 Sep;4(5):740-748. doi: 10.1016/j.euf.2016.09.002. Epub 2016 Sep 22.

PMID:
28753789
16.

Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell-Cell Communication in Renal Cell Carcinoma.

Butz H, Nofech-Mozes R, Ding Q, Khella HWZ, Szabó PM, Jewett M, Finelli A, Lee J, Ordon M, Stewart R, Krylov S, Yousef GM.

Eur Urol Focus. 2016 Jun;2(2):210-218. doi: 10.1016/j.euf.2015.11.006. Epub 2015 Dec 12.

PMID:
28723537
17.

Liquid biopsy: a step forward towards precision medicine in urologic malignancies.

Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM.

Mol Cancer. 2017 Apr 14;16(1):80. doi: 10.1186/s12943-017-0644-5. Review.

18.

miR-10b is a prognostic marker in clear cell renal cell carcinoma.

Khella HWZ, Daniel N, Youssef L, Scorilas A, Nofech-Mozes R, Mirham L, Krylov SN, Liandeau E, Krizova A, Finelli A, Cheng Y, Yousef GM.

J Clin Pathol. 2017 Oct;70(10):854-859. doi: 10.1136/jclinpath-2017-204341. Epub 2017 Mar 30.

PMID:
28360191
19.

Accurate MicroRNA Analysis in Crude Cell Lysate by Capillary Electrophoresis-Based Hybridization Assay in Comparison with Quantitative Reverse Transcription-Polymerase Chain Reaction.

Hu L, Stasheuski AS, Wegman DW, Wu N, Yang BB, Hayder H, Peng C, Liu SK, Yousef GM, Krylov SN.

Anal Chem. 2017 Apr 18;89(8):4743-4748. doi: 10.1021/acs.analchem.7b00707. Epub 2017 Apr 4.

PMID:
28339187
20.

Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study.

Di Michele J, Rotondo F, Kovacs K, Syro LV, Yousef GM, Cusimano MD, Di Ieva A.

Pathol Oncol Res. 2017 Oct;23(4):803-809. doi: 10.1007/s12253-017-0196-4. Epub 2017 Jan 13.

PMID:
28084580
21.

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.

White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM.

Br J Cancer. 2017 Mar 14;116(6):e3. doi: 10.1038/bjc.2016.441. Epub 2017 Jan 12. No abstract available.

22.

miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2.

Wang C, Zhang W, Zhang L, Chen X, Liu F, Zhang J, Guan S, Sun Y, Chen P, Wang D, Un Nesa E, Cheng Y, Yousef GM.

Br J Cancer. 2016 Dec 6;115(12):1548-1554. doi: 10.1038/bjc.2016.367. Epub 2016 Nov 10. Erratum in: Br J Cancer. 2018 Feb 20;:.

23.

The translational potential of microRNAs as biofluid markers of urological tumours.

Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K.

Nat Rev Urol. 2016 Dec;13(12):734-752. doi: 10.1038/nrurol.2016.193. Epub 2016 Nov 2. Review.

PMID:
27804986
24.

The Use of Targeted Therapies for Precision Medicine in Oncology.

White Al-Habeeb N, Kulasingam V, Diamandis EP, Yousef GM, Tsongalis GJ, Vermeulen L, Zhu Z, Kamel-Reid S.

Clin Chem. 2016 Dec;62(12):1556-1564. Epub 2016 Sep 27. No abstract available.

25.

MicroRNA Theranostics in Prostate Cancer Precision Medicine.

Matin F, Jeet V, Clements JA, Yousef GM, Batra J.

Clin Chem. 2016 Oct;62(10):1318-33. doi: 10.1373/clinchem.2015.242800. Epub 2016 Aug 18. Review.

26.

Neuropilin-1 is a receptor for extracellular miRNA and AGO2/miRNA complexes and mediates the internalization of miRNAs that modulate cell function.

Prud'homme GJ, Glinka Y, Lichner Z, Yousef GM.

Oncotarget. 2016 Oct 18;7(42):68057-68071. doi: 10.18632/oncotarget.10929.

27.

An integrated proteomic and peptidomic assessment of the normal human urinome.

Di Meo A, Batruch I, Yousef AG, Pasic MD, Diamandis EP, Yousef GM.

Clin Chem Lab Med. 2017 Feb 1;55(2):237-247. doi: 10.1515/cclm-2016-0390.

PMID:
27394047
28.

Performance of residents using digital images versus glass slides on certification examination in anatomical pathology: a mixed methods pilot study.

Mirham L, Naugler C, Hayes M, Ismiil N, Belisle A, Sade S, Streutker C, MacMillan C, Rasty G, Popovic S, Joseph M, Gabril M, Barnes P, Hegele RG, Carter B, Yousef GM.

CMAJ Open. 2016 Feb 25;4(1):E88-94. doi: 10.9778/cmajo.20140075. eCollection 2016 Jan-Mar.

29.

Malignancies in a renal transplant population: The St. Michael's Hospital experience.

Saleeb R, Faragalla H, Yousef GM, Stewart R, Streutker CJ.

Urol Ann. 2016 Apr-Jun;8(2):163-7. doi: 10.4103/0974-7796.165712.

30.

Proteomics and peptidomics: moving toward precision medicine in urological malignancies.

Di Meo A, Pasic MD, Yousef GM.

Oncotarget. 2016 Aug 9;7(32):52460-52474. doi: 10.18632/oncotarget.8931. Review.

31.

KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Sidiropoulos KG, Ding Q, Pampalakis G, White NM, Boulos P, Sotiropoulou G, Yousef GM.

Mol Oncol. 2016 Aug;10(7):993-1007. doi: 10.1016/j.molonc.2016.03.008. Epub 2016 Apr 8.

32.

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.

Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.

J Natl Cancer Inst. 2016 Apr 8;108(8). doi: 10.1093/jnci/djw030. Print 2016 Aug.

33.

Omics for personalized medicine: defining the current we swim in.

Ibrahim R, Pasic M, Yousef GM.

Expert Rev Mol Diagn. 2016 Jul;16(7):719-22. doi: 10.1586/14737159.2016.1164601. Epub 2016 Apr 6. No abstract available.

PMID:
26959799
34.

MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.

Nofech-Mozes R, Khella HW, Scorilas A, Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans A, Yousef GM.

Cancer Med. 2016 Apr;5(4):656-64. doi: 10.1002/cam4.631. Epub 2016 Feb 10.

35.

Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system.

Rotondo F, Butz H, Syro LV, Yousef GM, Di Ieva A, Restrepo LM, Quintanar-Stephano A, Berczi I, Kovacs K.

Pituitary. 2016 Aug;19(4):345-55. doi: 10.1007/s11102-015-0703-0. Review.

PMID:
26762848
36.

Achieving Single-Nucleotide Specificity in Direct Quantitative Analysis of Multiple MicroRNAs (DQAMmiR).

Wegman DW, Ghasemi F, Stasheuski AS, Khorshidi A, Yang BB, Liu SK, Yousef GM, Krylov SN.

Anal Chem. 2016 Feb 16;88(4):2472-7. doi: 10.1021/acs.analchem.5b04682. Epub 2016 Jan 26.

PMID:
26756139
37.

S100A11 is a potential prognostic marker for clear cell renal cell carcinoma.

Gabril M, Girgis H, Scorilas A, Rotondo F, Wala S, Bjarnason GA, Ding Q, Evans A, Tawedrous E, Pasic M, Finelli A, Al-Haddad S, Yousef GM.

Clin Exp Metastasis. 2016 Jan;33(1):63-71.

PMID:
26472670
38.

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.

Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU.

Oncotarget. 2015 Nov 17;6(36):39088-97. doi: 10.18632/oncotarget.5142. Review.

39.

Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.

Kolin DL, Sy K, Rotondo F, Bassily MN, Kovacs K, Brezden-Masley C, Streutker CJ, Yousef GM.

Tumour Biol. 2016 Jan;37(1):437-46. doi: 10.1007/s13277-015-3802-7. Epub 2015 Jul 30.

PMID:
26224476
40.

miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

Khella HWZ, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, Dharsee M, Latif A, Pasic MD, Lianidou E, Bjarnason GA, Yousef GM.

Mol Ther. 2015 Nov;23(11):1748-1758. doi: 10.1038/mt.2015.129. Epub 2015 Jul 23.

41.

Personalized Medicine in Kidney Cancer: Learning How to Walk Before We Run.

Yousef GM.

Eur Urol. 2015 Dec;68(6):1021-2. doi: 10.1016/j.eururo.2015.06.037. Epub 2015 Jul 9. No abstract available.

PMID:
26166627
42.

An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.

Wala SJ, Karamchandani JR, Saleeb R, Evans A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, Lianidou E, Yousef GM.

Mol Oncol. 2015 Oct;9(8):1667-77. doi: 10.1016/j.molonc.2015.04.007. Epub 2015 May 14.

43.

Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.

White-Al Habeeb NM, Di Meo A, Scorilas A, Rotondo F, Masui O, Seivwright A, Gabril M, Girgis AH, Jewett MA, Yousef GM.

Clin Exp Metastasis. 2015 Aug;32(6):531-41. doi: 10.1007/s10585-015-9725-2. Epub 2015 Jun 3.

PMID:
26037892
44.

miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways.

Lichner Z, Ding Q, Samaan S, Saleh C, Nasser A, Al-Haddad S, Samuel JN, Fleshner NE, Stephan C, Jung K, Yousef GM.

J Pathol. 2015 Oct;237(2):226-37. doi: 10.1002/path.4568. Epub 2015 Jul 24.

PMID:
26011734
45.

Malignancies arising in allograft kidneys, with a first reported translocation RCC post-transplantation: A case series.

Saleeb R, Faragalla H, Yousef GM, Stewart R, Streutker CJ.

Pathol Res Pract. 2015 Aug;211(8):584-7. doi: 10.1016/j.prp.2015.04.009. Epub 2015 Apr 30.

PMID:
26008778
46.

miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1.

Butz H, Szabó PM, Khella HW, Nofech-Mozes R, Patocs A, Yousef GM.

Oncotarget. 2015 May 20;6(14):12543-57.

47.

miRSNP-Based Approach Identifies a miRNA That Regulates Prostate-Specific Antigen in an Allele-Specific Manner.

Yousef GM.

Cancer Discov. 2015 Apr;5(4):351-2. doi: 10.1158/2159-8290.CD-15-0230.

48.

Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.

Papadopoulos EI, Yousef GM, Scorilas A.

Tumour Biol. 2015 May;36(5):3197-207. doi: 10.1007/s13277-014-2190-8. Epub 2015 Apr 2.

PMID:
25833690
49.

Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes.

Papadopoulos EI, Yousef GM, Scorilas A.

Biomed Pharmacother. 2015 Mar;70:33-40. doi: 10.1016/j.biopha.2014.12.043. Epub 2015 Jan 9.

PMID:
25776476
50.

The miRNA-Kallikrein interactions: adding a new dimension.

Pasic MD, Sotiropoulou G, Yousef GM.

Cell Cycle. 2015;14(5):691-2. doi: 10.1080/15384101.2015.1006541. No abstract available.

Supplemental Content

Loading ...
Support Center